Biotie Therapies - Major shareholder announcements

Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE 11 January 2011 at 6.15 p.m.

Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

Biotie Therapies Corp. ("Company" or "Biotie") has gained knowledge of the
notifications regarding changes in holdings in accordance with Chapter 2,
Section 9 of the Finnish Securities Markets Act, described below.

The notifications received by the Company concern the changes in holdings in the
Company of UCB A/S, 5AM Partners LLC (through 5AM Ventures LLC and 5AM Co-
investors LLC), Novo A/S as well as Abingworth Manangement Limited (through
Abingworth Bioventures IV LP and Abingworth Bioventures IV Executives LP).

The mentioned parties are parties to a Combination Agreement entered into on 10
January 2011 among the Company, Synosia Therapeutics Holding AG ("Synosia") as
well as Synosia's shareholders and warrant holders, described in more detail in
a stock exchange release issued on 11 January 2011, under which agreement the
Company will issue 161,448,371 shares to the shareholders and warrant holders of
Synosia in an acquisition of the entire issued share capital and outstanding
warrants of Synosia (the "Transaction") upon completion of the Transaction. In
connection with the Transaction, the Company will issue 14,912,155 to Synosia to
be held in treasury and used to satisfy future potential exercise of Synosia's
options. The completion of the Transaction is subject to the necessary
resolutions passed by the Company's shareholders at the Extraordinary General
Meeting of Shareholders to be held on 1 February 2011, the approval by the
Finnish Financial Supervisory Authority of the prospectus in relation to the
listing of the issued shares as well as certain other conditions.

According to the notifications received by the Company, none of the notifying
parties currently hold shares or votes in the Company and the resulting holdings
of shares and votes in the Company of the notifying parties after possible
completion of the Transaction and the registration of the shares to be issued
with the Finnish Trade Register would be as follows:

Name              Number of shares  Voting rights     Share of      Share of
                  to be received    shares to be      share capital voting
                  subject to        received subject  (%)           rights (%)
                  completion of     to completion of
                  Transaction       Transaction

UCB A/S           31,486,996        31,486,996        8.94          9.76

5AM Ventures LLC  14,590,660        14,590,660        4.14          4.52
(controlled by
5AM Partners LLC)

5AM Co-investors  2,070,363         2,070,363         0.59          0.64
LLC (controlled
by 5AM Partners
LLC)

5AM Partners LLC  16,661,023        16,661,023        4.73          5.16
(through 5AM
Ventures LLC and
5AM Co-investors
LLC) in total

Novo A/S          26,158,853        26,158,853        7.42          8.11

Abingworth        16,551,331        16,551,331        4.70          5.13
Bioventures IV LP
(controlled by
Abingworth
Management
Limited)

Abingworth        141,927           141,927           0.04          0.04
Bioventures IV
Executives LP
(controlled by
Abingworth
Management
Limited)

Abingworth        16,693,258        16,693,258        4.74          5.17
Management
Limited (through
Abingworth
Bioventures IV LP
and Abingworth
Bioventures IV
Executives LP) in
total



The number of voting rights and percentages presented above are calculated based
on number of shares and voting rights to be obtained upon completion of the
Transaction taking into account the treasury shares held by the Company on the
date of the notification.

On the date hereof, the registered number of shares in Biotie Therapies Corp. is
176,003,931. Of these shares 14,747,084 are held by the Company and the number
of outstanding shares and voting rights attached to the shares amounts thus to
161,256,847. Subject to the completion of the Transaction and subsequent to the
subscription and registration of the new shares to be issued in connection with
the Transaction, the aggregate number of Biotie shares will be 352,364,457. Of
these shares, 29,659,239 will be held by the Company or its group companies.



Turku, 11 January 2011



Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail:virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com


[HUG#1478919]